Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.

William G Wierda, Andrew Rawstron, Florence Cymbalista, Xavier Badoux, Davide Rossi, Jennifer R Brown, Alexander Egle (Co-author), Virginia Abello, Eduardo Cervera Ceballos, Yair Herishanu, Stephen P Mulligan, Carsten U Niemann, Colin P Diong, Teoman Soysal, Ritsuro Suzuki, Hoa T T Tran, Shang-Ju Wu, Carolyn Owen, Stephan Stilgenbauer, Paolo GhiaPeter Hillmen

Research output: Contribution to journalReview articlepeer-review

49 Citations (Web of Science)
Original languageEnglish
Pages (from-to)3059-3072
JournalLEUKEMIA
Volume35
Issue number11
DOIs
Publication statusPublished - 2021

Keywords

  • PREVIOUSLY UNTREATED PATIENTS
  • OPEN-LABEL
  • FLOW-CYTOMETRY
  • INDEPENDENT PREDICTOR
  • RITUXIMAB REGIMEN
  • 1ST-LINE THERAPY
  • PROGRESSION-FREE
  • FREE SURVIVAL
  • END-POINT
  • PHASE-II

Cite this